[fk_cart_menu]
[fk_cart_menu]

Cellular Peptide

PT-141

Bremelanotide
Vyleesi
CAS: 189691-06-3
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

A 7-acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical research.

Dosage
Quantity
$29.99
BUNDLE & SAVE

Fri, May 8 - Thu, May 14

Free shipment protection

Overnight shipping available

We Accept

Free shipping

on orders over $150

Damage

protection

Secure checkout

256-bit SSL

Compound Information

Technical specifications

MOLECULAR PROFILE

What Is PT-141?

Cyclic heptapeptide analog of alpha-MSH, active metabolite of Melanotan II

Cyclic Peptide
FDA Approved

Type:

Cyclic heptapeptide

CAS Number:

189691-06-3

Molecular Formula:

C50H68N14O10

Molecular Weight:

1025.2 g/mol

Acids:

7 residues

Sequence:

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH

  • PubChem Database

STORAGE REQUIREMENTS

Stability Information

Handle with care to maintain potency

Light sensitive
Refrigerate

Lyophilized (powder)

-20°C · protect from light

Reconstituted

2-8°C · use within 30 days

Auto-injector (Vyleesi)

Room temperature

DEVELOPMENT STATUS

Regulatory Information

Developed by Palatin Technologies, approved by FDA

Developer:

Palatin Technologies

Marketing:

AMAG Pharmaceuticals

FDA Approval:

June 21, 2019

Trade Name:

Vyleesi

Indication:

HSDD in premenopausal women

Male Use:

Not approved (research only)

Sources & References

Peer-reviewed research

OBSTETRICS & GYNECOLOGY

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

2019 · DOI: 10.1097/AOG… · PMID: 31599840
Kingsberg SA, Clayton AH, Portman D…

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

PT-141: a melanocortin agonist for the treatment of sexual dysfunction

2004 · PMID: 12851303
Diamond LE, Earle DC, Rosen RC, et al.

JOURNAL OF SEXUAL MEDICINE

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by...

2006 · DOI: 10.1111/j.1743… · PMID: 16839319
Diamond LE, Earle DC, Heiman JR, et al.

JOURNAL OF WOMEN’S HEALTH

Reported Event Profile of Bremelanotide Across the Clinical Development Program

2019 · PMID: 31625062
Kozlovskii II, Andreeva LA, Myasoedov…

FDA

Vyleesi (bremelanotide) Prescribing Information

2019

MEDICINA (KAUNAS)

Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder

2022 · PMID: 35056399

PUBCHEM DATABASE

Bremelanotide - Compound Summary (CID 9941379)

  • IMPORTANT RESEARCH NOTICE

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

All the research peptides you need, with the peace of mind and research community at your fingertips.

Shop Now

Research updates from The Glow Club

Subscribe for catalog updates, new research compounds, and quality documentation news

For researchers and labs. No spam, unsubscribe anytime.

Researcher verification

Glow Club sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.

By entering, you confirm you meet the qualifications above. Glow Club products are sold for research use only and are not intended for human consumption.

Not a researcher? Exit